SCHEMBL650100

SCHEMBL650100

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC(F)F)cc1)CC1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.40
TSHR P16473 4/20 0.33
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 3/20 0.33
CYP3A4 P08684 3/20 0.33
HSD17B10 Q99714 3/20 0.33
HPGD P15428 2/20 0.33
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33
MDM2 Q00987 3/20 0.33
CCR4 P51679 1/20 0.32
BACE1 P56817 2/20 0.32
HDAC1 Q13547 1/20 0.32
CRHR1 P34998 1/20 0.32
BCHE P06276 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HTT P42858 1/20 0.32
ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648763 0.91 C5AR1 (0.40) C5AR1TSHRALDH1A1KDM4ECYP3A4
SCHEMBL5137594 0.90 C5AR1 (0.42) C5AR1DRD2DRD3
SCHEMBL5136823 0.90 C5AR1 (0.42) C5AR1TSHRALDH1A1KDM4ECYP3A4
SCHEMBL5137557 0.90 C5AR1 (0.42) C5AR1TSHRALDH1A1KDM4ECYP3A4
SCHEMBL648871 0.90 C5AR1 (0.38) C5AR1TSHRALDH1A1KDM4EHSD17B10
SCHEMBL647827 0.89 C5AR1 (0.41) C5AR1TSHRALDH1A1KDM4ECYP3A4
SCHEMBL1913034 0.89 C5AR1 (0.38) C5AR1TSHRALDH1A1MDM2HDAC1
SCHEMBL5135713 0.89 C5AR1 (0.44) C5AR1TSHRALDH1A1KDM4ECYP3A4
SCHEMBL5137864 0.89 C5AR1 (0.44) C5AR1TSHRALDH1A1KDM4ECYP3A4
SCHEMBL651033 0.89 C5AR1 (0.44) C5AR1TSHRALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed